DDM College of Pharmacy, Gondpur Banehra, Una, Himachal Pradesh, India
T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are aggressive hematologic malignancies characterized by the uncontrolled proliferation of immature T-lymphoid precursors. Despite advances in multi-agent chemotherapy, outcomes for patients with relapsed or refractory disease remain poor, necessitating the development of targeted therapeutic strategies. Nelarabine, a prodrug of the purine nucleoside analog arabinosylguanine (ara-G), has demonstrated selective cytotoxicity toward T-lymphoblasts. Once metabolized intracellularly, ara-G is incorporated into DNA, leading to inhibition of DNA synthesis and induction of apoptosis. Clinical studies have shown that nelarabine is effective in inducing remission in patients with relapsed or refractory T-ALL and T-LBL, both as a monotherapy and in combination with other chemotherapeutic agents. Its use has been associated with improved response rates, enabling some patients to proceed to hematopoietic stem cell transplantation. However, neurotoxicity remains a significant dose-limiting adverse effect, requiring careful patient monitoring and dose adjustment. This review highlights the pharmacological profile, clinical efficacy, safety considerations, and evolving therapeutic role of nelarabine in the management of T-cell lymphoblastic malignancies.
NELARABINE
IUPAC Name: (2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl) oxolane-3,4-diol
Molecular Weight: 297.27 g/mol
Molecular Formula: C11H15N5O5
Molecular Structure:
Introduction
Nelarabine is an anticancer chemotherapeutic compound used to treat T-cell malignancies such as acute lymphoblastic leukaemia (ALL). Nelarabine is the prodrug of 9-β-D-arabinofuranosylguanine (ARA-G), and acts as a nucleoside analog of guanosine, inhibiting DNA synthesis. (1,2,3,4)
The pharmacokinetics of nelarabine have been thoroughly investigated, and the results have shown that ARA-GTP preferentially accumulates in malignant T-cells. Numerous T-cell malignancies have shown clinical responses to nelarabine, which seem to be correlated with a comparatively high intracellular concentration of ARA-GTP in comparison to nonresponders. Nelarabine's clinical use in treating adult and paediatric patients with relapsed or refractory T-cell acute lymphoblastic leukaemia or T-cell lymphoblastic lymphoma is thus explained by this special pharmacological characteristic. (5,6,7,8)
Mechanism Of Action
History
Radiation therapy, chemotherapy, and surgery have been the standard cancer treatment approaches for many years. The majority of tumours still have a bad prognosis, despite the fact that these techniques aid in improving the disease. Immunotherapy has shown a lot of promise in the treatment of tumours in recent years. The patient's own T cells are used in chimeric antigen receptor T-cell immunotherapy (CAR-T) to produce chimeric antigen receptors. Tumour-associated antigens are recognized by the chimeric antigen receptor (CAR), which then destroys tumour cells. Haematological malignancies have responded well to CAR-T treatment. The first CAR-T was authorized by the FDA in 2017 to treat B-cell acute lymphoblastic leukaemia (ALL). The FDA authorized CAR-T for the treatment of B-cell lymphoma in October of that same year. (9,10,11,12)
In recent years, CAR-T has been the focus of research to develop and strengthen the therapeutic efficacy. A summary is provided of the CAR structure, the CAR-T therapeutic targets, side effects, and steps taken to enhance the course of treatment. The goal of this study is to draw attention to recent—and perhaps overlooked—discoveries about the use of chimeric antigen receptor T cells to treat haematological malignancies. (13,14,15,16,17)
Monotherapy
Although it is frequently used in combination regimens, nelarabine, an antimetabolite prodrug, is licensed as monotherapy for adolescents and adults with relapsed and refractory T-cell acute lymphoblastic leukaemia and lymphoma (R/R T-ALL/LBL). 44 consecutive patients with R/R T-ALL/LBL were examined retrospectively; 29 of them received combination therapy, primarily etoposide and cyclophosphamide (23, 79%), while 15 received monotherapy. With 18 children under the age of 18, the median age was 19 years old (range: 2–69). 24 patients (55%) experienced complete remission following a median of 1 (range, 1-3) cycles of treatment, 62% (18/29) with combination therapy, and 40% (6/15) with monotherapy (P =.21). (18,19,20)
Interaction
|
DRUG |
INTERACTION |
|
INTEGRATE DRUG-DRUG |
|
|
Abatacept |
The risk or severity of adverse effects can be increased when Nelarabine is combined with Abatacept. |
|
Abciximab |
The risk or severity of bleeding can be increased when Abciximab is combined with Nelarabine. |
|
Acenocoumarin |
The risk or severity of bleeding can be increased when Acenocoumarin is combined with Nelarabine. |
|
Acetylsalicylic acid |
The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Nelarabine. |
|
Interferon alfa-n1 |
The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Nelarabine. |
|
Darbepoetin alfa |
The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nelarabine. |
|
Urokinase |
The risk or severity of bleeding can be increased when Urokinase is combined with Nelarabine. |
|
Reteplase |
The risk or severity of bleeding can be increased when Reteplase is combined with Nelarabine. (21,22) |
Refractory T-cell Malignancies
A clinical trial at the NIH Clinical Centre may be available to adults with a T-cell cancer that has not responded to or returned after at least one line of treatment. Although they can develop into cancer, T cells are essential for the body's immune response and cancer monitoring. A rare and diverse class of leukaemia’s and lymphomas that arise from T-cells are known as T-cell malignancies (TCMs). A combination of chemotherapeutic medications is typically used to treat TCM patients, however this only works in around one-third of instances. The prognosis is quite bad if the disease returns after this course of treatment. An investigation into a TCM therapeutic approach is being led by Milos Miljkovic, M.D., M.Sc., Assistant Research Physician in the Lymphoid Malignancies Branch. (23,24,25,26)
This treatment consists of four medications: lenalidomide, dexamethasone, oral 5-azacitidine, and romidepsin. Romidepsin slows the growth of cancer cells and causes cell death by interfering with their genetic composition. Azacitidine is integrated into the DNA of cancer cells. This leads to cell death and impairs the cells' ability to operate normally. Dexamethasone is an anti-inflammatory corticosteroid that resembles a hormone that the adrenal glands naturally generate. Lenalidomide stops tumour blood vessels from growing, which eventually kills the cells. For patients with relapsed or refractory TCM, researchers are attempting to ascertain the safety, adverse effects, and optimal dosage of this four-drug combination. (27,28,29,30)
REFERENCES
Deepak Kumar, Anshu Walia, Nitin Kumar, Shalu, Therapeutic Role of Nelarabine in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 1779-1784. https://doi.org/10.5281/zenodo.20085050
10.5281/zenodo.20085050
